<DOC>
	<DOCNO>NCT02134028</DOCNO>
	<brief_summary>Primary Objective : Evaluate long-term safety tolerability dupilumab patient asthma participate previous dupilumab asthma study ( DRI12544 , PDY14192 , EFC13579 , EFC13691 ) . Secondary Objectives : Evaluate efficacy dupilumab patient asthma participate previous dupilumab asthma clinical study . Evaluate dupilumab patient asthma participate previous dupilumab asthma clinical study , regard : - Systemic exposure - Anti-drug antibody - Biomarkers</brief_summary>
	<brief_title>Long-Term Safety Evaluation Dupilumab Patients With Asthma ( LIBERTY ASTHMA TRAVERSE )</brief_title>
	<detailed_description>A screening period , 3 week , apply patient come DRI12544 study . The total study duration , per patient , maximum 108 week ( 111 week consider maximum screening period 3 week Study DRI12544 ) patient enrol prior Amendment 04 approval maximum 60 week patient enrol Amendment 04 approval .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Inclusion criterion : Patients asthma complete treatment period previous dupilumab asthma clinical study ( ie , PDY14192 , EFC13579 EFC13691 ) patient asthma complete treatment followup period previous dupilumab asthma Study DRI12544 . Exclusion criterion : Patients experience hypersensitivity reaction Investigational Medicinal Product ( IMP ) previous dupilumab asthma study , , opinion Investigator , could indicate continue treatment dupilumab , may present unreasonable risk patient . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>